Oncology Today—February 2, 2026
???? CytoDyn funds TNBC expanded access for leronlimab [1] [US • 27 Jan 2026]
https://www.cytodyn.com/newsroom/press-releas...ded-access
Context: EAP aims to provide access to patients ineligible for trials and observe PD-L1 induction to inform potential ICI combinations.
Key point: A benefactor will fund an Expanded Access Program for leronlimab in advanced TNBC, with WEP Clinical as CRO and opening targeted for March 2026 pending FDA allowance.
Implication: May expand screening, initiation, and follow-up at scale.
https://www.lqventures.com/oncology-today-feb...ucidquest/